Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Cancer / Oncology News

Cisplatin/S-1 Offers Important Benefits Over Treatment Standard In Advanced Gastric Cancer

rate icon Editor's Choice
Main Category: Cancer / Oncology
Also Included In: Ear, Nose and Throat;  Colorectal Cancer;  GastroIntestinal / Gastroenterology
Article Date: 22 Jun 2009 - 11:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

ORLANDO - Cisplatin/S-1 (CS) is non-inferior to cisplatin/5-fluorouracil (CF) for the treatment of advanced gastric/gastro-esophageal carcinoma and at the same time offers important safety improvements, according to phase III results released recently at a meeting of the American Society for Clinical Oncology (ASCO).

S-1 is an investigational oral fluorouracil (FU) anticancer agent that combines tegafur, which is a pro-drug of 5-FU; gimeracil, which prevents 5-FU degradation by the body; and oteracil, which decreases 5-FU-related diarrhea. S-1 is given orally, while 5-FU and cisplatin are both administered by infusion.

Notably, the new data also showed superior overall survival in patients with diffuse-type histology, a group with a historically low survival rate.

"CS is an optimal substitute for CF in the treatment of advanced gastric cancer," Jaffer A. Ajani, M.D., professor of medicine at the M.D. Anderson Cancer Center in Houston Texas, said.

Dr. Ajani was the principal investigator of the study, which is known as the First-Line Advanced Gastric Cancer Study (FLAGS).

His group randomized patients to either S-1 (25 mg/m2 bid, d 1-21)/cisplatin (75 mg/m2 d1) q 28 d or 5-FU (1,000 mg/m2/d 5-d infusion)/cisplatin (100 mg/m2 d 1 ) q 28 d.

The primary endpoint was overall survival.

Results in 1,029 treated patients showed that the median overall survival was 8.6 months in patients randomized to CS and 7.9 months in patients assigned to CF, HR=0.92, p=0.1983.

As in earlier analyses of the FLAGS trial, CS-treated patients had significantly fewer grade 3-4 hematologic and grade 3 or greater non-hematologic toxicities than CF-treated patients and significantly fewer treatment-related deaths.

An unplanned non-inferiority analysis revealed that the mortality risk with CS decreased to a level that was determined by rigorous criteria to be non-inferior to the level achieved by the reference treatment (HR=0.92, p=0.0068).

The overall median survival in the 590 patients with diffuse-type histology was 9.0 months for CS patients and 7.1 months for CF patients, HR=0.83, p=.0413.

Dr. Ajani noted that the overall decline in the rate of gastric cancer in the U.S. applies to the intestinal type and added that the rate of the diffuse type has actually increased. In fact, data from 1973 through 2000 show that while the intestinal type decreased by 52% from 1973 through 2000, the diffuse type increased by 441% during that same period. Given the surge in diffuse-type gastric cancer, the results are particularly relevant, he said.

Gastric cancer is fourth most common malignancy worldwide and is the second most common cause of cancer-related deaths.

Written by Jill Stein
Jill Stein is a Paris-based freelance medical writer.
jillstein03(at)gmail.com
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today


Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Cellphones Cause Brain Tumors, Says New Report By International EMF Collaborative
26 Aug 2009
A new report, "Cellphones and Brain Tumors: 15 Reasons for Concern, Science, Spin and the Truth Behind Interphone," was released today by a collaborative of international EMF activists...


Stages of Breast Cancer image Stages of Breast Cancer

Breast cancer stages tell us the characteristics of the cancer and if it has spread beyond the breast tissue. Doctors can use this information to guide treatment decisions. Learn how staging is vital in determining next steps...

Living with Breast Cancer image Living with Breast Cancer

There are many options for treating breast cancer, including surgery, hormonal treatments, radiation and chemotherapy. All of these treatments have potential physical and emotional side effects. Discover how two women went through treatment and what they did to cope...

View more videos...